ADPT Stock: Price, Earnings History and SEC Filings
Adaptive Biotechnologies Corporation (ADPT) last traded at $26.64, down 5.43% on the latest session and down 7.8% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.10 against an analyst estimate of $-0.13, a beat of 23.1%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ADPT earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 29, 2026 | $-0.10 | $-0.13 | +23.08% |
| Mar 2026 | May 5, 2026 | $-0.13 | $-0.16 | +18.75% |
| Dec 2025 | Feb 5, 2026 | $-0.09 | $-0.19 | +52.63% |
| Sep 2025 | Nov 5, 2025 | $-0.15 | $-0.16 | +6.25% |
ADPT beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How ADPT reacts to earnings
Across its last 8 earnings releases, ADPT moved 10.8% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-07-29 | After close | +7.18% |
| 2026-05-05 | After close | +4.72% |
| 2026-02-05 | After close | -4.25% |
| 2026-01-12 | Before open | +15.86% |
| 2025-11-05 | After close | -11.54% |
| 2025-08-05 | After close | +5.79% |
| 2025-05-01 | After close | +33.70% |
| 2025-02-11 | After close | -3.21% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
ADPT financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $277M | -$59M | -$49M | -21.5% | $-0.39 |
| 2024 | $179M | -$159M | -$99M | -89.1% | $-1.08 |
| 2023 | $170M | -$225M | -$167M | -132.3% | $-1.56 |
| 2022 | $185M | -$200M | -$200M | -108.0% | $-1.40 |
| 2021 | $154M | -$207M | -$254M | -134.3% | $-1.48 |
| 2020 | $98M | -$146M | -$168M | -148.6% | $-1.11 |
| 2019 | $85M | -$69M | $194M | -80.6% | – |
| 2018 | $56M | -$46M | -$39M | -83.4% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for ADPT
- 10-Q · Aug 4, 2026
- 8-K · Jul 29, 2026Results of operations, Officer or director change, Financial statements and exhibits
- 8-K · Jun 22, 2026Material agreement, Agreement terminated, New financial obligation
- 8-K · Jun 15, 2026Other events, Financial statements and exhibits
- 8-K · Jun 9, 2026Shareholder vote
- 10-Q · May 5, 2026
- 8-K · May 5, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 24, 2026
- 10-K · Feb 26, 2026
- 8-K · Feb 5, 2026Results of operations, Financial statements and exhibits
Insider filing activity
ADPT insiders filed 17 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
ADPT news
- TELO Genomics Expands Multi-Center Clinical Studies to Advance Comparative Validation of TELO-MRD Against Next-Generation SequencingOct 29, 2026 · finance.yahoo.com
- Can You Still Buy Tempus AI Stock Today?Oct 28, 2026 · trefis.com
- Adaptive Biotechnologies Corp. (ADPT) Rallies on Earnings Beat, Raised Outlook, and Cash-Flow TargetsOct 27, 2026 · finance.yahoo.com
- What Happens To Tempus AI Stock If Its Cash Burn Continues?Oct 26, 2026 · trefis.com
- Should You Be Worried About Tempus AI Stock?Oct 20, 2026 · trefis.com
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation (ADPT) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in WA. Its fiscal year ends in December.